Vice President, Clinical

Craig Berman, M.D. has over 17 years of experience in drug development and held increasing leadership positions. Most recently, as a Vice President of Clinical Development at QED Therapeutics. Dr. Berman lead the clinical development of PEGPH20 at Halozyme from 2016-2018, cabozantinib at Exelixis 2013-2015, and enzalutamide at Medivation (currently Pfizer) 2009-2013, including successful NDA and launch. Dr. Berman has worked on several immune oncology programs including, GVAX whole cell vaccine at Cell Genesys, intratumoral injection of TLR-9 agonists in combination with pembrolizumab at Dynavax, and PEGPH20 in combination with atezolizumab in collaboration with Genentech and Halozyme. Dr. Berman received a B.A. in Chemistry from Northwestern University in Evanston, an M.D. from the University of Colorado Health Sciences Center and completed a residency in urology at the University of Iowa and post-residency training in urologic oncology at the University of Colorado.